Last reviewed · How we verify
IMOJEV
IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection.
IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection. Used for Prevention of Japanese encephalitis in endemic regions.
At a glance
| Generic name | IMOJEV |
|---|---|
| Also known as | Japanese Encephalitis Chimeric Virus Vaccine, JE-YF17D vaccine |
| Sponsor | SK Bioscience Co., Ltd. |
| Drug class | Live attenuated vaccine |
| Target | Japanese encephalitis virus |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
IMOJEV contains a weakened strain of Japanese encephalitis virus that replicates in vaccinated individuals without causing disease, thereby priming both cellular and humoral immune responses. This allows the immune system to recognize and neutralize wild-type Japanese encephalitis virus upon natural exposure. The vaccine is designed to provide long-term protection against Japanese encephalitis, a mosquito-borne viral disease prevalent in Asia.
Approved indications
- Prevention of Japanese encephalitis in endemic regions
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (PHASE1, PHASE2)
- Flavivirus Cross-priming Potential of IMOJEV (NA)
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (PHASE2)
- Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
- Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV (PHASE3)
- Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects (PHASE3)
- Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea (PHASE3)
- Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMOJEV CI brief — competitive landscape report
- IMOJEV updates RSS · CI watch RSS
- SK Bioscience Co., Ltd. portfolio CI